GlassScriptPhysician profile
John C Thompson
NPI 1770663890
$2,715.56
in general payments reported to CMS, 2019-2025
22 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,234 · 2020: $121 · 2021: $296 · 2022: $488 · 2023: $298 · 2024: $155 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $575.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $494.37 | 2019-2024 | Farxiga |
| Mallinckrodt Enterprises LLC | $321.87 | 2019 | |
| Opko Pharmaceuticals, LLC | $261.64 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $202.71 | 2019-2020 | |
| Fresenius USA Marketing, INC. | $188.02 | 2019-2022 | |
| Amgen INC. | $171.54 | 2019 | |
| Aurinia Pharma U.S., INC. | $155.89 | 2021-2022 | |
| Calliditas Therapeutics US INC. | $124.99 | 2023 | Tarpeyo |
| Ardelyx, INC. | $121.84 | 2025 | Xphozah 30 Mg |
| Glaxosmithkline, LLC. | $114.63 | 2019-2022 | |
| Vifor Pharma, INC. | $101.50 | 2019-2022 | |
| Horizon Therapeutics Plc | $79.25 | 2019 | |
| Daiichi Sankyo INC. | $51.35 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.39 | 2021-2022 | |
| Apellis Pharmaceuticals, INC. | $48.07 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $44.26 | 2019 | |
| Akebia Therapeutics INC | $39.04 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $38.89 | 2020-2022 | |
| Travere Therapeutics, INC. | $37.20 | 2019-2020 | |
| Nxstage Medical, INC. | $33.48 | 2024 | |
| Alexion Pharmaceuticals, INC. | $23.17 | 2019 | |
| Edwards Lifesciences Corporation | $12.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.